IP Group PLC Carisma announces $53m Series A funding round

TIDMIPO

IP Group PLC

27 June 2018

 
 FOR RELEASE ON   27 June 2018 
 

IP Group - Portfolio company Carisma Therapeutics announces $53m Series A funding round

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is pleased to note that US-based portfolio company Carisma Therapeutics Inc. ("Carisma" or "the Company"), has announced a $53 million Series A fundraising.

Carisma Therapeutics' discovery and development efforts are focused on its proprietary CAR-Macrophage platform, uniquely combining antigen recognition with the effector function of macrophages. Initial applications include targeting and killing solid tumors. The Company's therapeutic candidates also leverage macrophage antigen-presenting cell biology with the potential to mount an adaptive immune response. Carisma anticipates initiating clinical development in 2019.

The financing was led by AbbVie Ventures and HealthCap and includes existing seed investors IP Group, Penn Medicine and Grazia Equity. Carisma is also proud to welcome new investors Wellington Partners, TPG Biotech, MRL Ventures Fund and Agent Capital.

IP Group has committed to invest a total of $8.5m of the round, which is tranched and subject to the achievement of certain milestones. The Group has invested $4.25 million in the first tranche of the fundraising.

For more information, please contact:

IP Group plc - www.ipgroupplc.com

 
 Alan Aubrey, Chief Executive 
  Officer                             [phone] 
 Greg Smith, Chief Financial 
  Officer 
                                      [phone]/+44 (0) 
 Liz Vaughan-Adams, Communications     7979 853802 
 

IP Group North America -- www.ipgroup-inc.com

 
 Frank De Maria    [phone] 
 

Charlotte Street Partners

 
 Andrew Wilson    [phone] 
 Martha Walsh     [phone] 
 

Notes for editors

About IP Group

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

For more information, please visit our website at www.ipgroupplc.com.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAGMGZVNVZGRZM

(END) Dow Jones Newswires

June 27, 2018 02:30 ET (06:30 GMT)